Is CSF neurofilament light chain measurement relevant for MS?
作者信息
Matsui Makoto
机构信息
From the Department of Neurology, Kanazawa Medical University, Uchinada, Japan.
出版信息
Neurol Neuroimmunol Neuroinflamm. 2020 Sep 14;7(6). doi: 10.1212/NXI.0000000000000886. Print 2020 Nov 5.
Abstract
摘要
相似文献
1
Is CSF neurofilament light chain measurement relevant for MS?脑脊液神经丝轻链测量对多发性硬化症是否有意义？
Neurol Neuroimmunol Neuroinflamm. 2020 Sep 14;7(6). doi: 10.1212/NXI.0000000000000886. Print 2020 Nov 5.
2
The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
Mult Scler. 2015 Sep;21(10):1240-2. doi: 10.1177/1352458515589774. Epub 2015 Aug 4.
3
The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
Mult Scler. 2015 Sep;21(10):1239-40. doi: 10.1177/1352458515578773. Epub 2015 Mar 31.
4
The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.多发性硬化症治疗效果的唯一确切衡量标准是脑脊液神经丝水平：评论。
Mult Scler. 2015 Sep;21(10):1242-3. doi: 10.1177/1352458515599682. Epub 2015 Aug 4.
5
CSF neurofilament light: A universal risk biomarker in multiple sclerosis?脑脊液神经丝轻链：多发性硬化症的通用风险生物标志物？
Neurology. 2016 Sep 13;87(11):1068-9. doi: 10.1212/WNL.0000000000003107. Epub 2016 Aug 12.
6
Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.脑脊液中的神经丝蛋白——多发性硬化症疾病活动和长期预后的生物标志物
Mult Scler. 2016 Aug;22(9):1112-3. doi: 10.1177/1352458516658560. Epub 2016 Jun 30.
7
Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain.有前景的生物标志物血液神经丝轻链面临的挑战与机遇
JAMA Neurol. 2023 Jun 1;80(6):542-543. doi: 10.1001/jamaneurol.2023.0394.
8
Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.神经丝轻链：迈向多发性硬化症疾病生物标志物的重要一步。
Neurology. 2019 Mar 5;92(10):451-452. doi: 10.1212/WNL.0000000000007022. Epub 2019 Feb 8.
9
Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?血清神经丝轻链作为多发性硬化症残疾的预后标志物：我们做到了吗？
Neurology. 2020 Jun 9;94(23):1013-1014. doi: 10.1212/WNL.0000000000009576. Epub 2020 May 20.
10
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.脑脊液神经丝轻链追踪多发性硬化症中的认知障碍。
J Neurol. 2019 Sep;266(9):2157-2163. doi: 10.1007/s00415-019-09398-7. Epub 2019 May 25.
本文引用的文献
1
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.脑脊液神经丝轻链检测作为辅助确定 MS 治疗策略的手段。
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 21;7(6). doi: 10.1212/NXI.0000000000000880. Print 2020 Nov.
2
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.血清 GFAP 和神经丝轻链作为 NMOSD 疾病活动和残疾的生物标志物。
Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160. Epub 2019 Aug 30.
3
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.血液神经丝轻链作为 MS 疾病活动和治疗反应的生物标志物。
Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.
4
Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.神经丝轻链血清水平与多发性硬化症的10年磁共振成像结果相关。
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.
5
Neurofilaments as biomarkers in neurological disorders.神经丝作为神经紊乱的生物标志物。
Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z.
6
Neurofilaments and 10-year follow-up in multiple sclerosis.神经丝与多发性硬化症的 10 年随访。
Mult Scler. 2018 Sep;24(10):1301-1307. doi: 10.1177/1352458518782005. Epub 2018 Aug 1.
7
Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.多发性硬化症随访期间的神经丝水平、疾病活动和脑容量。
J Neuroinflammation. 2018 Jul 18;15(1):209. doi: 10.1186/s12974-018-1249-7.
8
Neurofilament light chain level is a weak risk factor for the development of MS.神经丝轻链水平是多发性硬化症发生的一个微弱风险因素。
Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12.
9
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症中芬戈莫德与脑脊液神经丝轻链水平
Neurology. 2015 Apr 21;84(16):1639-43. doi: 10.1212/WNL.0000000000001491. Epub 2015 Mar 25.
10
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.那他珠单抗可显著减少复发型多发性硬化症的轴突损伤。
Ann Neurol. 2011 Jan;69(1):83-9. doi: 10.1002/ana.22247. Epub 2010 Dec 8.
Zotero 插件